https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33412 Wed 31 Oct 2018 14:52:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45020 +/HER _2- , HR⁺/HER₂₊ , HR^-/HER ₂₊, HR^-/HER_2-). On average, women were 56 years of age at diagnosis and were followed for a median of 3.7 years. The majority were white (80%), had private health insurance (50%), and presented with poorly differentiated tumors (57%). Approximately 46% of the cancers were >5 cm. Most patients underwent mastectomy (94%) and received radiotherapy (71%). Differences by biologic subtypes were observed for grade, lymph node invasion, race, and tumor size (p < 0.0001). Patients experiencing pathologic complete response (pCR, 12%) vs. non-pCR had superior 5-year overall survival (OS) (77% vs. 54%) (p < 0.0001). Survival was poor for triple-negative (TN) tumors (37%) vs. other biologic subtypes (60%) (p < 0.0001). On multivariable analysis, TN-IBC, positive margins, and not receiving either chemotherapy, hormonal therapy or radiotherapy were independently associated with poor 5-year survival (p < 0.0001). In this analysis of IBC, categorized by biologic subtypes, we observed significant differential tumor, patient and treatment characteristics, and OS.]]> Wed 26 Oct 2022 10:17:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33411 Wed 19 Jan 2022 15:18:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30275 Wed 11 Apr 2018 15:08:06 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38162 75 years (RR = 2.3, p = 0.0026), female (RR = 1.6, p = 0.019), 5-meter walk test (5MWT) >7s (RR = 2.0, p = 0.0002) and not using home oxygen (RR = 2.9, p = 0.0084) were identified as independent predictive factors for discharge to a SNF. We report a parsimonious risk-stratification model that estimates the probability of being discharged to a SNF following TAVR. Our findings will facilitate making informed treatment decisions regarding this older patient population.]]> Wed 04 Aug 2021 18:58:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30618 Wed 02 Mar 2022 14:25:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33410 65 years of age who received RT survived significantly longer than those who did not receive RT (aHR = 0.53, 95% CI = 0.52–0.54). However, as women aged, those with comorbidities were less likely to receive RT (adjusted p-trend by age < 0.0001). Conclusions: The development of decision-making tools to assist clinicians, and older women with breast cancer and comorbidities, are needed to facilitate personalized treatment plans regarding RT. This is particularly relevant as the population ages and the number of women with breast cancer is expected to increase in the near future.]]> Tue 03 Sep 2019 18:19:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33647 Thu 27 Jan 2022 15:55:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30386 Thu 21 Oct 2021 12:51:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33646 1500 American College of Surgeons Commission on Cancer-accredited facilities, patients receiving PECT were shown to survive longer than those receiving POCRT.]]> Thu 17 Feb 2022 09:28:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32029 Mon 23 Sep 2019 13:08:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45478 65 years of age) presented with stage I-III pancreatic cancer. The majority of patients had tumors >2 cm size (82%), grade I/II (65%), lymphatic invasion (LI) (66%), and negative margins (76%). A survival advantage for adjuvant therapy was observed among all patients, independent of their risk-profile. For example, a patient =65 years of age, with early stage cancer (size =2 cm, grade I/II, -ve LI, -ve margins) who received adjuvant therapy had a 62% probability of being alive beyond three years (95%CI = 59%-66%). In contrast, the survival probability decreased to 53% (95%CI = 59%-66%) without adjuvant therapy. Conclusions: These results provide surgeons and patients with more accurate information regarding long-term survival, as well as the benefit of opting for adjuvant therapy after successful pancreatic surgery.]]> Fri 28 Oct 2022 14:36:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32036 Fri 01 Apr 2022 09:24:05 AEDT ]]>